Previously, we reported that using Dihydroartemisinin or small interfering RNA (siRNA) inactivates NF-κB and potentiates the antitumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo [24], [25]. This evidence concerns the gene NFKB1 and familial pancreatic carcinoma.